$599

Omada Releases IPO Pricing; EMA Concludes New Semaglutide Side Effect 

Two cardiometabolic-related news items have been observed: Omada announced its IPO price offering (view press release); and EMA concluded that non-arteritic anterior ischemic optic neuropathy is only a “very rare” side effect associated with semaglutide (view press release). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here